A link between Quality of Life scores in patients treated for Dry Eye Disease and Glaucoma is documented in the Jan. 2012 American Journal of Ophthalmology publication. As clinicians we need to be aware of the decrease in QOL with increasing Glaucoma severity by monitoring the ocular surface carefully.
Link Between Ocular Surface Disease and Quality of Life in Glaucoma Patients
To investigate the relationship between ocular surface disease and glaucoma-related quality of life (QOL), glaucoma severity and treatment in patients with open-angle glaucoma (OAG), Australian researchers conducted the following cross-sectional study in a clinical practice setting.
They enrolled 124 participants–patients with mild (n=48), moderate (n=34) or severe (n=19) glaucoma and 23 controls (glaucoma suspects) not receiving glaucoma treatment and stratified severity according to binocular visual field loss. Observed procedures included demographic information, the Ocular Surface Disease Index (OSDI) and Glaucoma Quality of Life-15 (GQL-15) questionnaires, which they administered. OSDI score, GQL-15 score, number and type of glaucoma medications, daily dose of benzalkonium chloride (BAK) and visual field indices served as main outcome measures.
The researchers reported that OSDI scores and the number of patients with OSD increased with increasing glaucoma severity (p<.001 and p<.005). They also noted that GQL-15 scores reflected decreased QOL with increasing glaucoma severity (p<.001) and that these trends were maintained after sub-stratification for age and sex. On univariate regression, OSDI was significantly correlated with GQL-15 summary score, glaucoma severity, multiple topical glaucoma medications, worse eye mean deviation and pattern standard deviation, use of topical beta-blockers, topical carbonic anhydrase inhibitors, daily dose of BAK and glaucoma filtration surgery. On multivariate regression, GQL-15 summary score (odds ration [OR] 4.14, 95% confidence interval [CI] 2.59–6.63, p<.001) and a daily dose of BAK >3 (OR 2.47, 95% CI 1.17–5.21, p=.018) were predictive of OSDI score.
OSD is more common in patients with increasing glaucoma severity and is associated with poorer glaucoma-related QOL and higher exposure to BAK, the study researchers concluded.
SOURCE: Skalicky SE, Goldberg I, McCluskey. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153(1):1–9.